Matinas BioPharma Holdings, Inc. Financial Ratios
MTNB|FY2024 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2024 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2024)
Return on Equity
-319.5%
Profit Margin
-
Net Income / Revenue
Asset Turnover
-
Revenue / Total Assets
Equity Multiplier
1.67
Total Assets / Equity
Profitability
Gross Margin
-
Operating Margin
-
EBITDA
-$24.0M
EBITDA Margin
-
Liquidity
Current Ratio
3.01
Quick Ratio
3.01
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
-
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2024 · SEC 10-K · Updated Jun 24, 2026
Earnings Quality
Accrual Ratio
-44.3%
-37.0pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.